Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures

References

• Eastell R, Cedel SL, Wahner HW. et al. Classification of vertebral fractures. J Bone Miner Res 1991;6:207–151Eastell R, Cedel SL, Wahner HW. et al. Classification of vertebral fractures. J Bone Miner Res 1991;6:207–15
   PubMed Web of Science ®Google Scholar
• Cauley JA, Zmuda JM, Wisniewski SR. et al. Bone mineral density and prevalent vertebral fractures in men and women. Osteoporos Int 2004;15:32–72Cauley JA, Zmuda JM, Wisniewski SR. et al. Bone mineral density and prevalent vertebral fractures in men and women. Osteoporos Int 2004;15:32–7
   PubMed Web of Science ®Google Scholar
• Genant HK, Jergas M, Palermo L. et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11:984–963Genant HK, Jergas M, Palermo L. et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11:984–96
   PubMed Web of Science ®Google Scholar
• Fechtenbaum J, Cropet C, Kolta S. et al. Reporting of vertebral fractures on spine X-rays. Osteoporos Int 2005;16:1823–64Fechtenbaum J, Cropet C, Kolta S. et al. Reporting of vertebral fractures on spine X-rays. Osteoporos Int 2005;16:1823–6
   PubMed Web of Science ®Google Scholar
• Delmas PD, van de LL, Watts NB. et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005;20:557–635Delmas PD, van de LL, Watts NB. et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005;20:557–63
   PubMed Web of Science ®Google Scholar
• Lips P. Invest in your bones: Quality of Life. Why prevent the first fracture? International Osteoporosis Foundation, 2003.6Lips P. Invest in your bones: Quality of Life. Why prevent the first fracture? International Osteoporosis Foundation, 2003.
   Google Scholar
• Ismail AA, O’Neill TW, Cooper C. et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 1998;8:291–77Ismail AA, O’Neill TW, Cooper C. et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 1998;8:291–7
   PubMed Web of Science ®Google Scholar
• Brenneman SK, Barrett-Connor E, Sajjan S. et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809–168Brenneman SK, Barrett-Connor E, Sajjan S. et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809–16
   PubMed Web of Science ®Google Scholar
• Fechtenbaum J, Cropet C, Kolta S. et al. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005;16:2175–99Fechtenbaum J, Cropet C, Kolta S. et al. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005;16:2175–9
   PubMed Web of Science ®Google Scholar
• Adachi JD, Ioannidis G, Olszynski WP. et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women BMC Musculoskelet Disord 2002;3:1110Adachi JD, Ioannidis G, Olszynski WP. et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women BMC Musculoskelet Disord 2002;3:11
   PubMed Web of Science ®Google Scholar
• Oleksik AM, Ewing S, Shen W. et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861–7011Oleksik AM, Ewing S, Shen W. et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861–70
   PubMed Web of Science ®Google Scholar
• Ensrud KC, Thompson DE, Cauley JA. et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241–912Ensrud KC, Thompson DE, Cauley JA. et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241–9
   PubMed Web of Science ®Google Scholar
• Kado DM, Browner WS, Palermo L. et al. Vertebral fractures and mortality in older women: the study of osteoporotic fractures. Arch Intern Med 1999;159:1215–2013Kado DM, Browner WS, Palermo L. et al. Vertebral fractures and mortality in older women: the study of osteoporotic fractures. Arch Intern Med 1999;159:1215–20
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D. et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–8214Center JR, Nguyen TV, Schneider D. et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–82
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ross PD, Palermo L. et al. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 1999;25:613–1915Nevitt MC, Ross PD, Palermo L. et al. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 1999;25:613–19
   Google Scholar
• Lindsay R, Silverman SL, Cooper C. et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–316Lindsay R, Silverman SL, Cooper C. et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L. et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner 1999;14:821–817Black DM, Arden NK, Palermo L. et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner 1999;14:821–8
   PubMed Web of Science ®Google Scholar
• Ismail AA, Cockerill W, Cooper C. et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001;12:85–9018Ismail AA, Cockerill W, Cooper C. et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001;12:85–90
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB. et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–3919Klotzbuecher CM, Ross PD, Landsman PB. et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–39
   PubMed Web of Science ®Google Scholar
• van Staa TP. Leufkens HG. Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002;13:624–920van Staa TP. Leufkens HG. Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002;13:624–9
   PubMed Web of Science ®Google Scholar
• Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int 2007;18:575–8421Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int 2007;18:575–84
   PubMed Web of Science ®Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367: 2010–1822Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367: 2010–18
   PubMed Web of Science ®Google Scholar
• Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 2007;37:1–1223Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 2007;37:1–12
   PubMed Web of Science ®Google Scholar
• Delmas PD, McClung MR, Zanchetta JR. et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36–4224Delmas PD, McClung MR, Zanchetta JR. et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36–42
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJA. Goettsch WG. Erkens JA. et al. Determinants of persistence with bisphosphonates: a study of women with postmenopausal osteoporosis. Clin Ther 2006;28: 236–4225Penning-van Beest FJA. Goettsch WG. Erkens JA. et al. Determinants of persistence with bisphosphonates: a study of women with postmenopausal osteoporosis. Clin Ther 2006;28: 236–42
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E. et al. The effects of strontium ranelate of the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–6826Meunier PJ, Roux C, Seeman E. et al. The effects of strontium ranelate of the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434–4127Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434–41
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD. et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2008;87:3609–1728Delmas PD, Ensrud KE, Adachi JD. et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2008;87:3609–17
   Google Scholar
• Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005;27:1–1129Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005;27:1–11
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. London: European Medicines Agency, 2005.30Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. London: European Medicines Agency, 2005.
   Google Scholar
• Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD: Food and Drug Administration, 2006.31Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD: Food and Drug Administration, 2006.
   Google Scholar
• Sambrook PN, Cameron ID, Chen JS. et al. Influence of fall-related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 2007;18:603–1032Sambrook PN, Cameron ID, Chen JS. et al. Influence of fall-related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 2007;18:603–10
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–4133Black DM, Cummings SR, Karpf DB. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241–934Chesnut CH, Skag A, Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280: 2077–8235Cummings SR, Black DM, Thompson DE. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280: 2077–82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J Am Med Assoc 1999;282:1344–5236Harris ST, Watts NB, Genant HK. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J Am Med Assoc 1999;282:1344–52
   Google Scholar
• Liberman UA, Weiss SR, Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437–4337Liberman UA, Weiss SR, Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437–43
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorensen OH. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–9138Reginster JY, Minne HW, Sorensen OH. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L. et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570–839Cranney A, Guyatt G, Griffith L. et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570–8
   PubMed Web of Science ®Google Scholar
• Armbrecht G, Blenk T, Chestnut CH. et al. Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology. J Clin Densitom 2008; 11:221–3140Armbrecht G, Blenk T, Chestnut CH. et al. Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology. J Clin Densitom 2008; 11:221–31
   PubMed Web of Science ®Google Scholar
• Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin. 2008;24:107–1941Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin. 2008;24:107–19
   PubMed Web of Science ®Google Scholar